Related Experiment Video
Updated: May 28, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Supramolecular peptide hydrogel epitope vaccine functionalized with CAR-T cells for the treatment of solid tumors
Pengxiang Yang1,2, Xiaomin Yao1, Xue Tian3
1Key Laboratory of Neuroregeneration of Jiangsu Province and Ministry of Education, Co-Innovation Center of Neuroregeneration, NMPA Key Laboratory for Research and Evaluation of Tissue Engineering Technology Products, Nantong University, 226001, Nantong, PR China.
Abstract:
Chimeric antigen receptor T-cell (CAR-T) therapy, which benefits from the perfect combination of gene editing techniques and antibody engineering, has shown outstanding clinical efficacy in hematological malignancies. Solid tumors present the next challenge due to their extremely complicated microenvironment and structural characteristics. Targeting efficiency and persistence are currently bottleneck issues in the clinical treatment of CAR-T. Beyond drugs and cytokines, biomaterials can modulate the immune response, assisting adoptive CAR-T cells in exerting their function. In this study, a supramolecular peptide hydrogel epitope vaccine was designed to serve as both a preparation medium and a reservoir for CAR-T cells. The self-assembling peptide formed a nanofiber scaffold through non-covalent interactions of amphiphilic amino acids and ion stabilizers. Firstly, the complementary peptide conjugated vaccine epitopes and CAR-T target sites were derived from different extracellular domains of the HER2 protein, and the combination treatment improved tumor antigen spreading and targeting efficiency. The epitope hydrogel promoted CAR-T cell proliferation, cytotoxic activity, and lymphocyte subpopulation transformation. Furthermore, the supramolecular peptide epitope vaccine encapsulated CAR-T (SPEV-CAR-T) induced endogenous humoral and cellular immune responses through a sustained release of the hydrogel and CAR-T cells, demonstrating superior anti-tumor effects in an in vivo mouse model. Most importantly, SPEV-CAR-T induced central memory cells in systemic immune tissues, addressing the poor persistence of single CAR-T therapy. The integration and complementation of active and passive immune responses in this all-in-one hydrogel epitope vaccine and CAR-T system facilitated a sequential succession of endogenous and exogenous immune responses, promoting persistent and specific tumor attack. SPEV-CAR-T showed superior therapeutic effects in solid tumors.
Insights
This study developed a novel supramolecular peptide hydrogel epitope vaccine combined with CAR-T cells. This SPEV-CAR-T therapy enhances targeting efficiency and persistence, showing superior anti-tumor effects in solid tumors.
Area of Science:
- Biomaterials Science
- Immunotherapy
- Oncology
Background:
- Chimeric antigen receptor T-cell (CAR-T) therapy shows promise in hematological malignancies but faces challenges in solid tumors due to the tumor microenvironment.
- Key limitations for CAR-T therapy in solid tumors include targeting efficiency and cell persistence.
- Biomaterials offer a strategy to modulate immune responses and enhance CAR-T cell function.
Purpose of the Study:
- To design a supramolecular peptide hydrogel epitope vaccine as a preparation medium and reservoir for CAR-T cells.
- To investigate the efficacy of this combined system (SPEV-CAR-T) in improving anti-tumor responses against solid tumors.
- To address the limitations of targeting efficiency and persistence in CAR-T therapy for solid tumors.
Main Methods:
- A self-assembling peptide hydrogel was created using non-covalent interactions.
- Complementary peptide-conjugated vaccine epitopes targeting HER2 were designed and combined with CAR-T cells.
- The SPEV-CAR-T system was evaluated for its effects on CAR-T cell proliferation, cytotoxicity, and immune response induction in vitro and in vivo.
Main Results:
- The epitope hydrogel promoted CAR-T cell proliferation, cytotoxic activity, and lymphocyte transformation.
- SPEV-CAR-T induced endogenous humoral and cellular immune responses, demonstrating superior anti-tumor effects in a mouse model.
- Crucially, SPEV-CAR-T induced central memory cells, improving the persistence of CAR-T therapy.
Conclusions:
- The integrated supramolecular peptide hydrogel epitope vaccine and CAR-T system (SPEV-CAR-T) offers a novel approach for solid tumor treatment.
- This all-in-one system facilitates sequential endogenous and exogenous immune responses for persistent and specific tumor attack.
- SPEV-CAR-T demonstrates superior therapeutic potential for solid tumors by overcoming current CAR-T limitations.
More Related Videos
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...